OverviewSuggest Edit

Novartis is a company that researches, develops, manufactures, and markets healthcare products. It comprises 2 global operation divisions: Innovative Medicines and Sandoz. The Innovative Medicines division offers patented prescription medicines, commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz division provides active ingredients and finished dosage forms of pharmaceuticals in the areas of the cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, and respiratory.
TypePublic
Founded1996
HQBasel, CH
Websitenovartis.com
Employee Ratings4.1

Latest Updates

Employees (est.) (Dec 2019)103,914(-16%)
Job Openings2
Revenue (FY, 2019)$47.4 B(-8%)
Share Price (Jan 2021)CHF85.3 (+3%)
Cybersecurity ratingAMore

Key People/Management at Novartis

Vasant Narasimhan

Vasant Narasimhan

Chief Executive Officer
Joerg Reinhardt

Joerg Reinhardt

Chairman
Bertrand Bodson

Bertrand Bodson

Chief Digital Officer
Steven Baert

Steven Baert

Chief People & Organization Officer
James Bradner

James Bradner

President of the Novartis Institutes for BioMedical Research (NIBR)
Harry Kirsch

Harry Kirsch

Chief Financial Officer
Show more

Novartis Office Locations

Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 164 other locations
Basel, CH (HQ)
Fabrikstrasse 2
Basel, CH
210, Lichtstrasse 35
Schweizerhalle, CH
Rothausstrasse 61
Stein, CH
Schaffhauserstrasse
Tirana, AL
Rruga Hoxha Tahsim 23
Bir Mourad Raïs, DZ
Said Hamdine
Show all (181)

Novartis Financials and Metrics

Novartis Revenue

Embed Graph
View revenue for all periods
Novartis's revenue was reported to be $47.45 b in FY, 2019 which is a 8.6% decrease from the previous period.
USD

Revenue (Q3, 2020)

12.3b

Gross profit (Q3, 2020)

8.5b

Gross profit margin (Q3, 2020), %

69.4%

Net income (Q3, 2020)

1.9b

EBIT (Q3, 2020)

2.4b

Market capitalization (15-Jan-2021)

194.0b

Closing stock price (15-Jan-2021)

85.3

Cash (30-Sept-2020)

9.0b

EV

223.2b
Novartis's current market capitalization is CHF194 b.
Annual
USDFY, 2017FY, 2018FY, 2019

Revenue

49.1b51.9b47.4b

Revenue growth, %

1%6%(9%)

Cost of goods sold

16.1b17.1b13.2b

Gross profit

33.0b34.8b34.2b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

12.7b13.2b12.8b11.1b11.8b12.2b12.3b11.3b12.3b

Cost of goods sold

4.1b4.2b4.3b3.0b3.1b3.5b3.3b3.2b3.8b

Gross profit

8.6b9.0b8.5b8.2b8.6b8.7b9.0b8.2b8.5b

Gross profit Margin, %

68%68%66%73%73%72%73%72%69%
Annual
USDFY, 2017FY, 2018FY, 2019

Cash

8.9b13.3b11.1b

Accounts Receivable

8.6b8.7b8.3b

Inventories

6.9b7.0b6.0b

Current Assets

28.2b35.6b29.5b
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

5.8b12.4b14.0b6.8b10.0b8.4b4.5b5.9b9.0b

Accounts Receivable

8.9b8.8b8.6b7.6b8.0b7.8b8.5b7.6b8.1b

Inventories

7.2b7.1b7.0b5.7b6.1b6.1b6.4b6.9b7.1b

Current Assets

33.1b32.1b34.1b52.4b28.3b26.7b23.1b23.9b29.0b
Annual
USDFY, 2017FY, 2018FY, 2019

Net Income

7.7b12.6b7.1b

Depreciation and Amortization

6.9b5.8b

Inventories

(533.0m)(382.0m)

Accounts Payable

309.0m553.0m
Quarterly
USDQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

2.0b9.8b11.4b1.9b4.0b6.0b2.2b4.0b6.0b

Depreciation and Amortization

4.9b1.4b2.5b3.9b1.4b3.1b

Cash From Operating Activities

2.5b6.5b10.5b2.4b5.5b10.1b2.5b6.5b9.6b

Purchases of PP&E

(359.0m)(690.0m)(1.1b)(282.0m)(561.0m)(918.0m)(237.0m)(475.0m)(754.0m)
USDFY, 2017

EV/EBIT

22.6 x

EV/CFO

15.5 x

Revenue/Employee

403.9k

Debt/Equity

0.4 x

Debt/Assets

0.2 x

Financial Leverage

1.8 x

P/E Ratio

22.2
Show all financial metrics

Novartis Operating Metrics

FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Major Approvals (US, EU, JP)

20 16 16 15

Major Submissions (US, EU, JP)

14 24 16 20 30

Patients Reached

972 m965 m927 m

Projects Entering Development Pipeline

8 5 9
Show all operating metrics

Novartis Acquisitions / Subsidiaries

Company NameDateDeal Size
Vedere BioOctober 29, 2020$280 m
AmblyotechApril 21, 2020
The Medicines CompanyNovember 25, 2019$9.70 b
XiidraMay 09, 2019$1.90 b
Novartis Inflammasome ResearchApril 02, 2019$1.58 b
CellforCureDecember 21, 2018
EndocyteOctober 18, 2018
AveXisApril 09, 2018$8.70 b
Advanced Accelerator ApplicationsOctober 30, 2017$3.90 b
Encore VisionDecember 20, 2016
Show more

Novartis Revenue Breakdown

Embed Graph

Novartis revenue breakdown by business segment: 20.5% from Sandoz and 79.5% from Innovative Medicines

Novartis revenue breakdown by geographic segment: 5.6% from Japan , 34.3% from United States, 5.1% from France, 8.7% from Germany and 46.3% from Other

Human Capital Metrics

Embed Graph
Show all human capital metrics

Novartis Cybersecurity Score

Cybersecurity ratingPremium dataset

A

94/100

SecurityScorecard logo

Novartis Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

60-79

out of 100

CSRHub logo

Novartis Online and Social Media Presence

Embed Graph

Novartis News and Updates

AveXis renamed Novartis Gene Therapies, signifying the growing importance of gene therapy to Novartis corporate strategy

Novartis has renamed the previously acquired AveXis to Novartis Gene Therapies.

New collaboration between Novartis and Africa Medical Supplies Platform to facilitate supply of COVID-19 related medicines

Novartis and the African Union (AU) through the Africa Medical Supplies Platform (AMSP) have announced a new collaboration to facilitate the supply of medicines from the Novartis Pandemic Response Portfolio to the AU member states and Caricom countries.

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

Ligelizumab is the first treatment to receive FDA Breakthrough Therapy designation in chronic spontaneous urticaria (CSU) in patients with an inadequate response to H1-antihistamines 1   Currently there are limited approved therapies for patients with CSU, also known as chronic…

Novartis ligelizumab (QGE031) receives FDA Breakthrough Therapy designation for patients with chronic spontaneous urticaria (CSU)

Novartis today announced that the U.S. Food and Drug Administration (FDA) has granted ligelizumab (QGE031) Breakthrough Therapy designation for the treatment of chronic spontaneous urticaria (CSU), also known as chronic idiopathic urticaria (CIU), in patients who have an inadequate response to H1-an…

Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene

Agreement expands Novartis Oncology portfolio, adding late-stage PD-1 for monotherapy and potential proprietary PD-1 combinations, driving mid- and long-term growth Novartis secures development and commercialization rights in North America, Europe, and Japan …
Show more

Novartis Frequently Asked Questions

  • When was Novartis founded?

    Novartis was founded in 1996.

  • Who are Novartis key executives?

    Novartis's key executives are Vasant Narasimhan, Joerg Reinhardt and Bertrand Bodson.

  • How many employees does Novartis have?

    Novartis has 103,914 employees.

  • What is Novartis revenue?

    Latest Novartis annual revenue is $47.4 b.

  • What is Novartis revenue per employee?

    Latest Novartis revenue per employee is $456.6 k.

  • Who are Novartis competitors?

    Competitors of Novartis include Bausch + Lomb, Immunomedics and Gilead Sciences.

  • Where is Novartis headquarters?

    Novartis headquarters is located at Fabrikstrasse 2, Basel.

  • Where are Novartis offices?

    Novartis has offices in Basel, Schweizerhalle, Stein, Broomfield and in 164 other locations.

  • How many offices does Novartis have?

    Novartis has 181 offices.